Prestige Biologics Co., Ltd. (KOSDAQ:334970)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,798.00
-6.00 (-0.33%)
At close: Jul 28, 2026

Prestige Biologics Cash Flow Statement

Millions KRW. Fiscal year is Jul - Jun.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Dec '22 Dec '21
Net Income
-35,425-27,469-29,374-39,442-49,718-39,378
Depreciation & Amortization
15,23213,08311,2318,4147,9383,921
Loss (Gain) From Sale of Assets
1.746.86-90.87-67.29-66.42-
Asset Writedown & Restructuring Costs
---646.03646.03-
Stock-Based Compensation
---54.88222.14294.5794.58
Other Operating Activities
970.18-6,728-11,35412,86014,94031,121
Change in Accounts Receivable
3,923-51.97674.2-1,0631,175-1,167
Change in Inventory
-9,714-4,7137,081-11,351-13,772-19,462
Change in Accounts Payable
1,0004,1892,461292.7-2,3172,954
Change in Unearned Revenue
--309.87-5.22-663.92147.48-307.31
Change in Other Net Operating Assets
32,1533,68511,0875,3236,608-4,226
Operating Cash Flow
8,142-18,308-8,345-24,830-34,124-25,750
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Dec '22 Dec '21
Capital Expenditures
-7,215-5,226-8,522-35,435-84,642-97,392
Sale of Property, Plant & Equipment
65.0572.88541,0811,105-
Sale (Purchase) of Intangibles
-753.28-430.06350.02-107.47-147.41-619
Other Investing Activities
6024.82191.11-19.2919.23101.18
Investing Cash Flow
-7,843-5,558-7,927-34,481-83,665-97,910

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Dec '22 Dec '21
Long-Term Debt Issued
----96,17274,685
Total Debt Issued
---56,50096,17274,685
Short-Term Debt Repaid
------2,700
Long-Term Debt Repaid
--95,031-913.51--59,912-3,736
Total Debt Repaid
-10,843-95,031-913.51-60,035-59,912-6,436
Net Debt Issued (Repaid)
-10,843-95,031-913.51-3,53536,26068,249
Issuance of Common Stock
1,11691,0421,31059,86760,24688,092
Other Financing Activities
-1.72-51.19-52.34-42.75-42.75-28.43
Financing Cash Flow
-9,729-4,041344.556,28996,463156,312

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-18.37-18.82--472.96-65.68-118.89
Miscellaneous Cash Flow Adjustments
---0-0-00
Net Cash Flow
-9,449-27,926-15,928-3,494-21,39232,533

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Dec '22 Dec '21
Free Cash Flow
926.76-23,534-16,867-60,265-118,767-123,142
Free Cash Flow Growth
------
Free Cash Flow Margin
5.14%-187.77%-777.63%-3451.94%-763002.69%-3816.18%
Free Cash Flow Per Share
10.74-319.14-275.63-1027.35-2295.00-2770.62
Levered Free Cash Flow
2,422-33,288-27,812--98,250-127,117
Unlevered Free Cash Flow
6,588-27,829-20,456--95,795-126,640

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Dec '22 Dec '21
Cash Interest Paid
2,0784,6863,3554,8314,764818.02
Cash Income Tax Paid
---11.84-40.39-18.5
Change in Working Capital
27,3632,79921,297-7,462-8,158-22,208